PMID- 22741564
OWN - NLM
STAT- MEDLINE
DCOM- 20130212
LR  - 20171116
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 27
IP  - 10
DP  - 2012 Oct
TI  - Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's 
      disease.
PG  - 1546-54
LID - 10.1111/j.1440-1746.2012.07220.x [doi]
AB  - No drug therapy is completely risk free, and the costs associated with 
      non-response and adverse effects can exceed the cost of the therapy. The ultimate 
      goal of pharmacogenetic research is to find robust genetic predictors of drug 
      response that enable the development of prospective genetic tests to reliably 
      identify patients at risk of non-response or of developing an adverse effect 
      prior to the drug being prescribed. Currently, thiopurine S-methyltransferase 
      (TPMT) deficiency is the only pharmacogenetic factor that is prospectively 
      assessed before azathioprine or 6-mercaptopurine immunomodulation is commenced in 
      patients with Crohn's disease (CD). As yet no other inherited determinant of drug 
      response has made the transition from bench to bedside for the management of this 
      disease. In this review we summarize what is known about TPMT deficiency and 
      explore whether there is evidence to support a role of other genetic 
      polymorphisms in predicting the response of CD patients to thiopurine drugs, 
      methotrexate, and anti-tumor necrosis factor alpha (TNFalpha) therapy.
CI  - (c) 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing 
      Asia Pty Ltd.
FAU - Roberts, Rebecca L
AU  - Roberts RL
AD  - Department of Surgical Sciences, Dunedin School of Medicine, Dunedin, New 
      Zealand. rebecca.roberts@otago.ac.nz
FAU - Barclay, Murray L
AU  - Barclay ML
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Genetic Markers)
RN  - 0 (Immunologic Factors)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - E7WED276I5 (Mercaptopurine)
RN  - MRK240IY2L (Azathioprine)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - Thiopurine S methyltranferase deficiency
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Azathioprine/therapeutic use
MH  - Biotransformation/genetics
MH  - Crohn Disease/*drug therapy/genetics/immunology
MH  - Drug Hypersensitivity/diagnosis/genetics
MH  - Drug Interactions
MH  - Genetic Markers
MH  - Genetic Predisposition to Disease
MH  - Genetic Testing
MH  - Humans
MH  - Immunologic Factors/adverse effects/pharmacokinetics/*therapeutic use
MH  - Infliximab
MH  - Mercaptopurine/therapeutic use
MH  - Methotrexate/therapeutic use
MH  - Patient Selection
MH  - *Pharmacogenetics
MH  - Phenotype
MH  - Polymorphism, Genetic
MH  - Precision Medicine
MH  - Purine-Pyrimidine Metabolism, Inborn Errors/diagnosis/genetics
MH  - Risk Assessment
MH  - Risk Factors
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2012/06/30 06:00
MHDA- 2013/02/13 06:00
CRDT- 2012/06/30 06:00
PHST- 2012/06/30 06:00 [entrez]
PHST- 2012/06/30 06:00 [pubmed]
PHST- 2013/02/13 06:00 [medline]
AID - 10.1111/j.1440-1746.2012.07220.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2012 Oct;27(10):1546-54. doi: 
      10.1111/j.1440-1746.2012.07220.x.